Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography

This study has been completed.
Information provided by (Responsible Party):
Chancellor of research, Urmia University of Medical Sciences
ClinicalTrials.gov Identifier:
First received: February 21, 2014
Last updated: June 13, 2015
Last verified: June 2015
The purpose of this study is to evaluate the effect of vitamin E on preventing from incidence of contrast induced acute kidney injury (CI-AKI) in the patients who undergone coronary angiography.

Condition Intervention Phase
Stable Angina
Unstable Angina
Non ST Segment Elevation Myocardial Infarction
Post MI
Drug: Vitamin E
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by Urmia University of Medical Sciences:

Primary Outcome Measures:
  • The development of CI-AKI in group receiving vitamin E compared with placebo [ Time Frame: Within 72 hours after coronary angiography ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Changes in the serum level of Cr and the amount of eGFR [ Time Frame: Within 72 hours ] [ Designated as safety issue: Yes ]

Enrollment: 284
Study Start Date: February 2014
Study Completion Date: June 2015
Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Active Comparator: Vit-E
600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography
Drug: Vitamin E
Other Name: Alpha-tocopherol


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. All patients whon have either stable coronary artery disease (CAD) or recent acute coronary disease (ACS) and are scheduled for coronary angiography.
  2. Patients who have eGFR ≤60 ml/min/1.73 m2

Exclusion Criteria:

  1. Allergy to contrast media
  2. Cardiogenic shock
  3. Pulmonary edema
  4. Overt cardiac failure or left ventricular ejection fraction ≤ 30%
  5. Acute kidney injury
  6. The history of receiving contrast media for any medical diagnostic or therapeutic procedures during previous 5 days
  7. The history of dialysis
  8. Being pregnant
  9. Having recent acute myocardial infarction
  10. Taking antioxidants and nephrotoxic drugs including NSAID and ACE-I on previous 2 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02070679

Iran, Islamic Republic of
Seyyed-al-Shohada Heart Center, UMSU
Urmia, West-Azerbaijan, Iran, Islamic Republic of
Taleghani Hospital, UMSU
Urmia, West-Azerbaijan, Iran, Islamic Republic of
Sponsors and Collaborators
Urmia University of Medical Sciences
  More Information

Responsible Party: Chancellor of research, Mir Hossein Seyyed-Mohammadzad, Urmia University of Medical Sciences
ClinicalTrials.gov Identifier: NCT02070679     History of Changes
Other Study ID Numbers: UMSU-Cardiology-1 
Study First Received: February 21, 2014
Last Updated: June 13, 2015
Health Authority: Iran: Ethics Committee

Keywords provided by Urmia University of Medical Sciences:
Vitamin E
Contrast-Induced Acute Kidney Injury
Coronary angiography

Additional relevant MeSH terms:
Acute Kidney Injury
Angina, Stable
Angina, Unstable
Myocardial Infarction
Angina Pectoris
Cardiovascular Diseases
Chest Pain
Heart Diseases
Kidney Diseases
Myocardial Ischemia
Renal Insufficiency
Signs and Symptoms
Urologic Diseases
Vascular Diseases
Vitamin E
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents

ClinicalTrials.gov processed this record on April 27, 2016